OCA
DFTX

Octagon Capital Advisors’s Definium Therapeutics DFTX Stock Holding History

Octagon Capital Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139M Buy
2,950,000
+510,000
+21% +$12.6M 12.47% 2
2026
Q1 		$46.1M Buy
2,440,000
+210,000
+9% +$3.56M 5.1% 5
2025
Q4 		$29.9M Buy
2,230,000
+100,000
+5% +$1.24M 3.63% 10
2025
Q3 		$25.1M Hold
2,130,000
– – 3.81% 10
2025
Q2 		$13.8M Sell
2,130,000
-888,000
-29% -$5.84M 3.03% 16
2025
Q1 		$17.7M Hold
3,018,000
– – 3.42% 9
2024
Q4 		$21M Hold
3,018,000
– – 3.46% 10
2024
Q3 		$17.2M Buy
3,018,000
+865,000
+40% +$6.02M 2.67% 14
2024
Q2 		$15.5M Hold
2,153,000
– – 2.44% 14
2024
Q1 		$20.2M Buy
+2,153,000
New +$12.3M 2.43% 13

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Octagon Capital Advisors's DFTX Position: Q2 2026 in Review

Octagon Capital Advisors increased its Definium Therapeutics (DFTX) stake by 21% in Q2 2026, buying an estimated $12.6M and bringing the position to 2,950,000 shares worth $139M. The position accounts for 12.47% of the portfolio, ranked #2.

Octagon Capital Advisors first reported a position in DFTX in Q1 2024 and has held it in 10 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Octagon Capital Advisors held 2,950,000 shares of Definium Therapeutics worth $139M as of Q2 2026.
  • Octagon Capital Advisors bought 510,000 Definium Therapeutics shares in Q2 2026, an estimated $12.6M.
  • Definium Therapeutics made up 12.47% of Octagon Capital Advisors's portfolio in Q2 2026, its #2 holding.
  • Octagon Capital Advisors first reported a position in Definium Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.